Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio
TheFly reported on February 10 that Truist Securities analyst Les Sulewski raised its price target on COLL to $58 from $55 and gave it a Buy rating. The analyst emphasized the robustness of the company...







